🇺🇸 FDA
Pipeline program

rAAVrh74.MHCK7.DYSF.DV

IRB15-00669

Phase 1 small_molecule completed

Quick answer

rAAVrh74.MHCK7.DYSF.DV for Dysferlinopathy is a Phase 1 program (small_molecule) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Sarepta Therapeutics
Indication
Dysferlinopathy
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials